U.S. Markets closed

Hemostemix Inc. (HEM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4050-0.0100 (-2.41%)
At close: 3:46PM EST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4150
Open0.4100
Bid0.4100 x 0
Ask0.4200 x 0
Day's Range0.4000 - 0.4200
52 Week Range0.0100 - 0.8000
Volume238,297
Avg. Volume461,619
Market Cap22.492M
Beta (5Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.1680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
    Newsfile

    Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval

    Calgary, Alberta--(Newsfile Corp. - February 11, 2021) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM; OTC: HMTXF) is pleased to announce it has contracted Protocol First to provide it with source document verification services. Protocol First's P1 Source Upload solution, which runs alongside any EDC system, allows site coordinators to upload un-redacted source data at the click of a button. The CRA/monitor can remote monitor the data, mark it as reviewed, issue queries ...

  • Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced
    Newsfile

    Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced

    Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021. A total 65 subjects who were enrolled in the trial, randomized 2:1 to receive ACP-01 or a placebo, will have completed the last follow-up appointments by March 31, 2021. The ...

  • Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
    Newsfile

    Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada

    Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) ("Hemostemix" or the "Company") is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech focused Canadian Small and Medium Enterprise (SMEs), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies."We are actively working ...